Two major storylines surge across the board! Nvidia sparks the AI boom, and crypto-related stocks go on a rampage together, with PURR jumping more than 20% in a single week+
August 28 update: This week, U.S. stocks strengthened again as AI earnings provided a catalyst alongside a rebound in the crypto market. In the close of trading on August 27 (U.S. Eastern Time), the S&P 500 rose about 0.7% for the week, the Nasdaq gained 1.4%, and the technology sector returned to the market’s main theme.
Nvidia delivered an earnings report that beat expectations, confirming that compute capacity demand remains robust. Sentiment across AI chips and the compute power industry chain fully recovered. Meanwhile, a rebound in bitcoin prices and slightly improved expectations around regulation also drew fresh capital interest back to crypto concept stocks such as MSTR, CRCL, and PURR. In the healthcare sector, Moderna’s momentum was boosted by clinical data for its mRNA cancer vaccine and approval of its updated COVID-19 vaccine; however, the market still has disagreements about its commercialization prospects.
Key weekly stock performance:
• MSTR (+12.04%): Strategy completed a share-selling operation of roughly $2 billion. It did not add to its bitcoin holdings, while keeping $1.59 billion in cash. As bitcoin recovered, the value of its bitcoin holdings plus cash buffer was re-priced by the market, and investors once again highlighted its leverage characteristics.
• CRCL (+7.43%): Bernstein maintained an “outperform the market” rating with a target price of $140. The firm believes USDC growth is not driven solely by policy tailwinds. Stablecoin payments and ongoing on-chain capital market demand continue to provide fundamental support, and the stock rose in a choppy but upward pattern this week.
• PURR (+20.58%): The heat in the Hyperliquid ecosystem continued. Trading capital focused on HYPE positions, regulatory improvements, and a beta-driven行情 in the DeFi sector. The company holds about $1.9 billion worth of HYPE, has zero debt, and surged on heavy volume on August 27. The stock’s small-cap status shows high volatility.
• NVDA (+9.35%): Q2 revenue was $96.22 billion, and Q3 guidance reached $108 billion. Demand for data center business continued to exceed expectations. After the earnings release, the stock jumped to as high as $227.98. The market faded concerns that AI capital expenditures may have peaked, confirming that compute demand is still expanding.
• MRNA (+2.79%): Positive news from mRNA melanoma vaccine data and FDA approval of an updated COVID-19 vaccine provided a boost, sending the stock higher intraday. But differences over the vaccine’s eligible indications and the timing of commercialization meant it pulled back after the spike, resulting in a modest weekly gain.
# Up 8.74% after Nvidia’s earnings report
August 28 update: This week, U.S. stocks strengthened again as AI earnings provided a catalyst alongside a rebound in the crypto market. In the close of trading on August 27 (U.S. Eastern Time), the S&P 500 rose about 0.7% for the week, the Nasdaq gained 1.4%, and the technology sector returned to the market’s main theme.
Nvidia delivered an earnings report that beat expectations, confirming that compute capacity demand remains robust. Sentiment across AI chips and the compute power industry chain fully recovered. Meanwhile, a rebound in bitcoin prices and slightly improved expectations around regulation also drew fresh capital interest back to crypto concept stocks such as MSTR, CRCL, and PURR. In the healthcare sector, Moderna’s momentum was boosted by clinical data for its mRNA cancer vaccine and approval of its updated COVID-19 vaccine; however, the market still has disagreements about its commercialization prospects.
Key weekly stock performance:
• MSTR (+12.04%): Strategy completed a share-selling operation of roughly $2 billion. It did not add to its bitcoin holdings, while keeping $1.59 billion in cash. As bitcoin recovered, the value of its bitcoin holdings plus cash buffer was re-priced by the market, and investors once again highlighted its leverage characteristics.
• CRCL (+7.43%): Bernstein maintained an “outperform the market” rating with a target price of $140. The firm believes USDC growth is not driven solely by policy tailwinds. Stablecoin payments and ongoing on-chain capital market demand continue to provide fundamental support, and the stock rose in a choppy but upward pattern this week.
• PURR (+20.58%): The heat in the Hyperliquid ecosystem continued. Trading capital focused on HYPE positions, regulatory improvements, and a beta-driven行情 in the DeFi sector. The company holds about $1.9 billion worth of HYPE, has zero debt, and surged on heavy volume on August 27. The stock’s small-cap status shows high volatility.
• NVDA (+9.35%): Q2 revenue was $96.22 billion, and Q3 guidance reached $108 billion. Demand for data center business continued to exceed expectations. After the earnings release, the stock jumped to as high as $227.98. The market faded concerns that AI capital expenditures may have peaked, confirming that compute demand is still expanding.
• MRNA (+2.79%): Positive news from mRNA melanoma vaccine data and FDA approval of an updated COVID-19 vaccine provided a boost, sending the stock higher intraday. But differences over the vaccine’s eligible indications and the timing of commercialization meant it pulled back after the spike, resulting in a modest weekly gain.
# Up 8.74% after Nvidia’s earnings report
